Talecris to pay down first-, second-lien bank debt with IPO proceeds

By Sara Rosenberg

New York, Sept. 15 - Talecris Biotherapeutics Holdings Corp. plans to repay first- and second-lien term loan borrowings using proceeds from the sale of common stock through an initial public offering, according to a news release.

Through the IPO, about 44.7 million shares are being offered. Of that amount, around 28.9 million are being sold by Talecris and around 15.8 million are being sold by the selling stockholder, Talecris Holdings LLC, which is owned by Cerberus Partners.

The IPO price is expected to be between $18 and $20 per share.

Talecris will not receive any of the proceeds from the offering of common stock by the selling stockholder.

Talecris is a Research Triangle Park, N.C.-based biotherapeutic and biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.